Biotherapeutics News and Research

RSS

Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment

New research out of Wake Forest University School of Medicine identifies the presence of cardiovascular risk factors as an indicator of how likely it is that elderly, hospitalized patients who receive intravenous immunoglobulin (IVIg) treatment will have a stroke or heart attack.

5 Mar 2009

Good bacteria may provide effective vehicle for an oral vaccine against anthrax

Researchers at North Carolina State University have discovered that the good bacteria found in dairy products and linked to positive health benefits in the human body might also be an effective vehicle for an oral vaccine that can provide immunity to anthrax exposure.

17 Feb 2009

FDA approves orphan drug ATryn anticoagulant

The U.S. Food and Drug Administration has issued its first approval for a biological product produced by genetically engineered (GE) animals.

8 Feb 2009

Recombinant human antithrombin drug decreases risk to pregnancy and surgery patients with hereditary antithrombin deficiency

Pregnancy and surgery patients with a serious blood disorder that causes excessive clotting have responded well to treatment with a man-made anti-clotting protein.

8 Dec 2008

CardioVascular BioTherapeutics doses first patient in trial for severe coronary heart disease

CardioVascular BioTherapeutics, Inc. , announced today that it has dosed the first patient in North America (NA) as part of its ACORD Phase II clinical trial to treat patients with severe coronary heart disease.

25 Nov 2008

FDA accepts ATryn biologics license application

The US Food and Drug Administration, or FDA, has accepted for review GTC Biotherapeutics, Inc.'s Biologics License Application, or BLA, for ATryn.

6 Oct 2008

FDA grants approval to Talecris Biotherapeutics for Gamunex for neurological disorder CIDP

Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted approval for Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a debilitating neurological disorder that results in muscle weakness and fatigue, which can lead to severe impairment of motor skills.

15 Sep 2008

FDA approves Gamunex for chronic inflammatory demyelinating polyneuropathy

The U.S. Food and Drug Administration has announced that it has approved an immune globulin product called Gamunex for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the legs and arms.

14 Sep 2008

FDA assigns priority review to ATryn from GTC Biotherapeutics

The US Food and Drug Administration, or FDA, has assigned Priority Review to GTC Biotherapeutics, Inc.'s Biologic License Application, or BLA, for ATryn.

4 Sep 2008

Oxygen Biotherapeutics develops gel version of Oxycyte for treating surface wounds

Oxygen Biotherapeutics, Inc. has announced that the company has developed a gel-like form of Oxycyte that it intends to investigate as a topical application for open wounds, abrasions and burns. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

12 Aug 2008

Roche starts acquisition process of ARIUS - fast tracks access to screening platform for antibody therapeutics

Roche and ARIUS Research Inc. have announced that the two companies have signed a definitive agreement for Roche to acquire ARIUS in an all-cash transaction at a price of approximately C$191 million.

23 Jul 2008

Compugen announces discovery of novel drug targets for cancer antibody therapeutics

Compugen Ltd. announced today the discovery of more than ten novel targets of antibody therapy for various types of solid and hematopoietic cancer.

11 Jun 2008

How to design a cancer-killing virus

One new way to treat individuals with cancer that is being developed is the use of viruses that infect and kill cancer cells while leaving normal cells unharmed.

25 Oct 2007

Clinical trial to evaluate glioblastoma multiforme vaccine commences at NYU

A clinical trial evaluating a brain cancer vaccine in patients with newly diagnosed brain cancer has begun at NYU Medical Center.

19 Oct 2007

Protalix BioTherapeutics receives FDA approval to initiate a phase III trial of prGCD

Protalix BioTherapeutics, Inc. has announced that it has received written notice from the United States Food and Drug Administration (FDA) that it may initiate a Phase III clinical trial in the United States of its lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD), for the treatment of Gaucher Disease, a lysosomal storage disorder in humans.

19 Apr 2007

Lexicon-Genentech reveals potential therapeutic targets

Lexicon Genetics Incorporated has announced that data was presented highlighting potential therapeutic targets related to its collaboration with Genentech, Inc. at the Society for Biomolecular Sciences 13th Annual Conference & Exhibition in Montreal, Canada.

19 Apr 2007

Heart Hospital begins experimental cell therapy

Physicians at the Heart Hospital became the first team in the UK to treat a patient with an experimental new therapy designed to repair damage to cardiac muscle resulting from a heart attack. If successful, this treatment would give doctors the ability to improve the hearts of people with heart failure, rather than just treating the symptoms.

6 Dec 2004

New understanding of how poxviruses jump from species to species

A Canadian study conducted at Robarts Research Institute sheds new light on how poxviruses can jump from species to species -- and will lead to further exploration of another potential candidate in the emerging field of “oncolytic viruses” to fight cancer.

25 Oct 2004

Maggots may help decrease the risk of post-operative infections

Maggots aren’t high on most people’s favorite-animals list. But maggots - specifically, the larvae of the green blowfly, Phaenicia sericata - can be helpful for the very reason they horrify.

16 Sep 2004

Genencor Sells Its Therapeutic Vaccine Program to Innogenetics

Genencor International, Inc. today announced that it has agreed to sell its therapeutic vaccine program to Belgian biotechnology company Innogenetics N.V. Innogenetics will develop and commercialize current product candidates in Genencor’s vaccine product portfolio as well as future products based on intellectual property and technology held by Genencor.

30 Mar 2004